Compare PLX & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLX | SIGA |
|---|---|---|
| Founded | 1993 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 207.1M | 223.8M |
| IPO Year | 1996 | 2016 |
| Metric | PLX | SIGA |
|---|---|---|
| Price | $2.90 | $2.41 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | ★ 990.1K | 535.8K |
| Earning Date | 11-10-2026 | 11-09-2026 |
| Dividend Yield | N/A | ★ 22.64% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.31 | 0.09 |
| Revenue | ★ $52,744,000.00 | N/A |
| Revenue This Year | $64.22 | N/A |
| Revenue Next Year | N/A | $205.62 |
| P/E Ratio | ★ $9.85 | $29.56 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.65 | $2.51 |
| 52 Week High | $3.19 | $7.11 |
| Indicator | PLX | SIGA |
|---|---|---|
| Relative Strength Index (RSI) | 56.51 | 28.24 |
| Support Level | $2.08 | N/A |
| Resistance Level | $3.19 | $3.43 |
| Average True Range (ATR) | 0.20 | 0.24 |
| MACD | 0.03 | -0.06 |
| Stochastic Oscillator | 71.74 | 1.21 |
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S. Government and international governments (including government-affiliated entities). The Company operates in one single operating and reportable segment, which includes all activities related to the sale of the Company's Oral and IV TPOXX as well as research and development services.